Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D James

Showing results (141-150 of 198) with videos related to

Pageof 20
Sort By:
JAMA Oncology|January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical TrialNicholas D James, Sarah J Pirrie, Ann M Pope, et al.
European Urology|March 4, 2019
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysisSarah Burdett, Liselotte M Boevé, Fiona C Ingleby, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
JAMA Oncology|February 27, 2025
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical TrialGianmarco Leone, Francesco Orlando, Peter Dutey-Magni, et al.
European Urology|July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trialGerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancerDaniel H Palmer, Vivien Mautner, Darius Mirza, et al.
BJU International|June 4, 2016
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, et al.
The Lancet. Oncology|May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Robert Coleman, Sten Nilsson, et al.
BMC Medicine|December 3, 2025
Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancerYa-Ting Chen, Jing Sui, Yu Yang, et al.
European Urology Oncology|August 6, 2021
Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder CancerTessel E Galesloot, Anne J Grotenhuis, Dimitar Kolev, et al.
Pageof 20

Showing results (141-150 of 198) with videos related to

Sort By:
Pageof 20
JAMA Oncology|January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical TrialNicholas D James, Sarah J Pirrie, Ann M Pope, et al.
European Urology|March 4, 2019
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysisSarah Burdett, Liselotte M Boevé, Fiona C Ingleby, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
JAMA Oncology|February 27, 2025
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical TrialGianmarco Leone, Francesco Orlando, Peter Dutey-Magni, et al.
European Urology|July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trialGerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancerDaniel H Palmer, Vivien Mautner, Darius Mirza, et al.
BJU International|June 4, 2016
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, et al.
The Lancet. Oncology|May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Robert Coleman, Sten Nilsson, et al.
BMC Medicine|December 3, 2025
Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancerYa-Ting Chen, Jing Sui, Yu Yang, et al.
European Urology Oncology|August 6, 2021
Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder CancerTessel E Galesloot, Anne J Grotenhuis, Dimitar Kolev, et al.
Pageof 20